}-3,7-dihydro-7-[2 methoxyethyl]-1,3-dimethyl-lH-purine-2,6-dione (MKS-492), a reported type III isozyme inhibitor of cyclic nucleotide phosphodiesterase, on antigen or platelet activating factor (PAF)-induced bronchoconstriction and allergic reactions in guinea pigs and rats were investigated. 1) MKS-492 inhibited antigen-induced bron choconstriction in guinea pigs. Aminophylline also inhibited the reaction. 2) MKS-492 inhibited PAF-in duced bronchoconstriction and inhibited the increase in airway responsiveness to histamine in guinea pigs, although aminophylline failed to affect these reactions. 3) MKS-492 relaxed guinea pig tracheal muscle in vitro more potently than aminophylline. 4) MKS-492 inhibited leukotriene B4 (LTB4)-induced airway eosinophilia in guinea pigs. 5) MKS-492 inhibited passive cutaneous anaphylaxis and mediator-induced skin reactions in rats more potently than aminophylline. Both drugs inhibited antigen and phospholipase A2 induced histamine release from guinea pig lung tissue. 6) MKS-492 inhibited PAF-induced 02 generation from guinea pig alveolar macrophages. These results indicate that MKS-492 is a more potent inhibitor of allergic bronchoconstriction and PAF or LTB4-induced inflammatory reactions in guinea pigs and the allergic cutaneous reactions in rats when compared to aminophylline.
Theophylline has been a useful drug for the treatment of asthma for over 50 years. Although some pharma cological actions of theophylline, such as phospho diesterase (PDE) inhibition and adenosine antagonism, have been studied, the precise mechanisms responsible for its activity in the treatment of asthma are not yet fully elucidated (1 5) . Among its actions, however, PDE inhibition has been considered to be important for asthma therapy. Recently, PDE isozymes have been characterized, and much attention has been paid to the application of distinct PDE isozyme inhibitors as a rem edy for asthma (6) (7) (8) (9) (10) (11) , because the data obtained may explain the relationship between PDE inhibition and the therapeutic effect of theophylline for asthma and may lead to the development of more effective drugs. The exist ence of PDE isozymes in airway smooth muscle and air way inflammatory cells has already been demonstrated by many investigators (7 -10) . In 1991, Torphy and Undem reported that the inhibition of type III or V PDE is relat ed to bronchodilation and that the inhibition of type IV PDE causes an anti-inflammatory effect in airways (8) . However, the anti-inflammatory action of type III PDE inhibitors (SK&F 94120 and sigazodan) is mainly exerted through a mechanism not involving the inhibition of inflammatory cell function (6, (12) (13) (14) (15) . A type IV PDE selective inhibitor, tibenelast, and type III and IV PDE inhibitors, benzafentrine and zardaverine, are reported to be effective anti-asthmatic agents (8, 9) . At present, however, only limited information is available about the action of PDE isozyme inhibitors.
R[+]-8-1[1 [3, 4 -Dimethoxyphenyl] -2-hydroxyethyl] amino } -3 , 7-dihydro-7 [2-methoxyethyl] -1, 3-dimethyl-1 H purine-2,6-dione (MKS-492) is a selective inhibitor of cyclic GMP-inhibited PDE (type III PDE), and it is reported to inhibit antigen-induced airway inflammation (16) (17) (18) . Many recent investigations have indicated the contribution of airway inflammation to the development of asthma (19) (20) (21) (22) . Therefore, in the present study, to elucidate the relationship between type III PDE inhibi tion and the therapeutic effect for asthma, the effects of MKS-492 on antigen or platelet activating factor (PAF) induced bronchoconstriction in guinea pigs and allergic inflammatory reactions in guinea pigs and rats were stud ied in comparison to those of aminophylline, which has a 2,000-times less potent inhibitory activity against type III PDE (16).
MATERIALS AND METHODS

Animals
Female Hartley guinea pigs weighing 250 300 g were used for preparation of antiserum. Male Hartley guinea pigs weighing 300 500 g were used for the other experi ments. In some studies, male Wistar rats weighing 180-220 g were also used. All animals were purchased from Japan SLC, Inc. (Hamamatsu).
Antigen and antiserum
Benzylpenicilloyl bovine-7-globulin (BPO-BGG) and bovine serum albumin (BPO-BSA) were used as antigens for the guinea pigs. Anti-BPO-BGG guinea pig serum was prepared according to the method described by Levine and Redmond (23) . The IgE antibody titer was 1 : 2", as estimated by 7-day homologous passive cutaneous anaphylaxis (PCA). Dinitrophenylated Ascaris suum ex tract (DNP-As) and bovine serum albumin (DNP-BSA) were used as antigens for rats. Anti-DNP-As serum was prepared according to the method described by Tada and Okumura (24) , with a slight modification. The IgE antibody titer of the antiserum preparation estimated by homologous PCA was 1 : 28.
Materials
MKS-492 was kindly donated by Sandoz Pharma, Ltd.
(Basel, Switzerland 
Antigen-induced bronchoconstriction
Guinea pigs were passively sensitized with anti-BPO BGG guinea pig serum (0.5 ml/kg) by an intravenous in jection via the forearm vein. Both 24 hr and 30 min before intravenous injection of antigen, metyrapone (5 mg/kg, i.v.), which inhibits 11j3-hydroxylase in glucocorticoid biosynthesis, was given to sensitized guinea pigs in order to decrease glucocorticoid levels, because the serum glucocorticoid levels in guinea pigs are much higher than those in humans, especially in bronchial asthmatic patients (25, 26) . The procedure for measuring alterations in respiration has been described previously (25) . In brief, at 48 hr after sensitization, the guinea pigs were anesthe tized with pentobarbital (50 mg/kg, i.p.). The trachea was cannulated (tracheotomy), and the cannula was con nected to both a transducer (MFP-1100, TV-142, TU-241, TP-602T; Nihon Kohden, Tokyo) and a respirometer (RM-25, RPM-6018; Nihon Kohden). Then the guinea pigs were challenged by intravenous injection of BPO BSA (30 pg/kg) saline solution. Alterations in respiration were measured by counting changes in the respiratory rate, and the volume and ratio of expiration time to inspi ration time. MKS-492 and aminophylline were admin istered intravenously 5 min before the antigen challenge.
PAF-induced bronchoconstriction and increase in airway responsiveness to histamine
To measure PAF-induced bronchoconstriction and increases in airway responsiveness, previously described procedures were employed (27) .
Guinea pigs were anesthetized with pentobarbital (10 mg/kg, i.p.) and phenobarbital (120 mg/kg, i.p.) and paralyzed with gallamine (10 mg/kg, i.m.). The animals were ventilated with air (8 ml/kg, 60 strokes/min) using a rodent ventilator (New England Medical Instruments, Inc., Medway, MA, USA). Bronchoconstriction was measured according to the overflow method described by Konzett and Rossler (28) using a bronchospasm trans ducer (model 7020; Ugo Basile, Varese, Italy) connected to the tracheal cannula.
Airway reactivity to intravenous injection of histamine (3 pg/kg) was determined according to the method de scribed by Anderson et al. (29) with a slight modification. Histamine was injected 2 times via the jugular vein to obtain a pre-challenge value. The interval of histamine injections was 7 min. Seven minutes after the latter injec tion of histamine, the animals were challenged with a sin gle bolus dose of PAF (25 ng/kg, i.v.), and then hista mine was again injected 7 min later. For the control, sa line containing 0.25% BSA (vehicle) was used instead of PAF. Drugs were injected intravenously 5 min before PAF injection. Data were expressed as the percentage of the post-challenge value against the pre-challenge value.
Studies of guinea pig tracheal muscle relaxation Guinea pigs were stunned and exsanguinated. The trachea was excised, trimmed of excess tissue, and cut lon gitudinally in the cartilage tissue area. The open trachea was cut into 16 to 20 segments. Four segments, tied together to form a chain, were placed in an organ bath containing Tyrode's solution. Changes in the tone of the preparation, with 0.5-g initial resting tension, were record ed isotonically (MEC, ME-4013; World Medical Co., Ltd., Nagoya). Drugs to be examined were added cumu latively after the carbachol (10-6 M)-caused contraction reached a plateau. Relaxing potency was calculated as a percentage of the relaxation induced by isoproterenol (10-6 M).
Measurement of leukocyte count in bronchoalveolar lavage fluid (BALF)
In order to measure the number of leukocytes in the airway, BALF was obtained from guinea pigs by the previously reported method (30) . Four hours after the intratracheal injection of LTB4 (10 leg), the animals were sacrificed by means of an intraperitoneal injection of pen tobarbital (260 mg/kg). BALF was obtained by the slow injection of 10 ml of sterile saline into the trachea using a cannula, after which the fluid was withdrawn. The num ber of nucleated cells in lavage fluid was counted in a Biirker chamber, and a differential count was made on a smear prepared using a cytocentrifuge and stained with May-Grunwald and Giemsa stain.
PCA and cutaneous reactions
PCA and cutaneous reactions caused by allergic chemi cal mediators were examined at the same time in the same rats (31) . As allergic mediators, histamine, 5-HT and LTC4 were used. On the shaved dorsal skin of rats, 6 reac tion sites were marked, and 0.1 ml of 40-fold diluted anti DNP-As serum was injected intradermally into 1 of the 6 reaction sites for passive sensitization. At the same time, 0.1 ml of saline was injected into another site as a control for PCA. Forty-eight hours after the sensitization, 0.1 ml of 10-5 g/ml of histamine, 5 x 10-'g/ml of 5-HT or 3 x 10-6 g/ml of LTC4 was injected into 3 of the 4 remain ing sites intradermally. The last site was used as a control for cutaneous reactions and received an injection of an equivalent volume of saline. Immediately after the injec tions of mediator solutions and saline, 1 mg of DNP-BSA and 5 mg of Evans blue dye dissolved in saline were given intravenously.
Thirty minutes later, the rats were sacrificed, and the reaction sites were excised for determi nation of extravasated dye. Each experimental group con sisted of 6 rats, and the reaction sites were rotated within the group. Extravasated dye in each reaction site was ex tracted and determined colorimetrically according to the method described by Katayama et al. (32) . PLA2-induced histamine release was obtained by incu bation of chopped lung tissue from non-sensitized guinea pigs with PLA2 (0.5 IU/ml) at 371C for 30 min. The re leased histamine was assayed as described above.
Measurement of superoxide anion (02-) production
The generation of superoxide anion (02-) was meas ured according to the method of Yamashita et al. (34) . Guinea pig alveolar macrophages were prepared accord ing to the previously described method (35) . In brief, the animals were killed by intraperitoneal injection of pen tobarbital (150 mg/kg). The trachea was cannulated, and the airway lumen was washed with three aliquots (10 ml) of saline containing 0.1076 BSA warmed at 371C. The lavage fluid from each animal was centrifuged (150 x g at 41C for 10 min). The cell pellets were gently washed with Ca 2+-, Mg2+-free Hanks' balanced salt solution (HBSS, pH 7.3) and finally suspended at 2 x 106 cells/ml in HBSS containing 0.1% BSA. These cells contained more than 92% alveolar macrophages as identified by May-Grun wald and Gimsa staining. These preparations always con tained more than 98% viable cells as measured by trypan blue staining. Cells in 1 ml HBSS containing 0.1016 BSA were pre-incubated with cytochrome C (1.24 mg/ml) and cytochalasin B (5 leg/ml). After 10 min, cells were stimu lated by PAF (10-6 g/ml) or PMA (2 x 10-' g/ml) for 10 min. Drugs to be tested were added 5 min before the stimulation. The reaction was terminated by transferring the test tubes into an ice bath, followed by centrifugation at 1,500 x g for 10 min at 41C. An aliquot of the super natant was then measured spectrophotometrically at 550 nm. The amount of reduced cytochrome C was calculated from the molar extinction coefficient of 21.1 mM-'cm-'. Results are expressed as the number of nanomoles of cyto chrome C reduced by superoxide dismutase.
Statistical analyses
Statistical analyses were performed by Student's t-test and Dunnett's multiple range test (36) .
RESULTS
Antigen-induced bronchoconstriction in vivo in guinea pigs
In metyrapone-treated guinea pigs, the antigen-induced bronchoconstriction and prolongation of the ratio of ex piration time to inspiration time were clearly potentiated as described before (25) . The effects of MKS-492 and aminophylline are indicated in Figs. 1 and 2 . MKS-492 at doses of 3 and 10 mg/kg inhibited antigen-induced bron choconstriction in a dose-related manner (Fig. 1) . In con trast, aminophylline at a dose of 3 mg/kg did not affect bronchoconstriction, although at a dose of 10 mg/kg, the drug inhibited it almost completely (Fig. 2) . Figure 3 shows the results of PAF-induced broncho constriction in guinea pigs. PAF (150 ng/kg administered intravenously) caused bronchoconstriction, causing an increase in air overflow of 75.6±4.30%, compared with the maximum contraction obtained by clamping off the tracheal cannula. MKS-492 at doses of 1 and 3 mg/kg completely inhibited the PAF-induced bronchoconstric tion, but the same doses of aminophylline failed to affect it. PAF-induced increase in airway responsiveness to hista mine Histamine (3 pg/kg) administered intravenously caused transient bronchoconstriction, causing an increase in air overflow of 12.2-L2.75% (n=12), compared with the maximum contraction obtained by clamping off the tracheal cannula. Although intravenous injection of PAF (25 ng/kg) produced a negligible bronchoconstriction by itself, it induced a significant increase (325.7-L36.3%) in airway responsiveness to histamine. When MKS-492 at doses of 1 and 3 mg/kg was administered 5 min before PAF injection, the PAF-induced increase in airway responsiveness to histamine was inhibited significantly (Fig. 4) . Aminophylline at doses of 1 and 3 mg/kg only showed a tendency of inhibition. ly. The IC50 value for MKS-492 was 1.2 x 10-5 M, although that for aminophylline was more than 10-4 M. L TB4-induced increase in leukocyte count in BALF LTB4 at a dose of 10 pg increased the number of total cells, eosinophils and neutrophils in BALF (Fig. 6) . When MKS-492 was administered intraperitoneally at doses of 30 and 100 mg/kg, 30 min before the injection of LTB4, the increases in eosinophils and neutrophils were inhibit ed. Aminophylline at a dose of 30 mg/kg also inhibited the increase of neutrophils.
PAF-induced bronchoconstriction in vivo in guinea pigs
PCA and mediator-induced cutaneous reactions Figure 7 indicates the results of PCA and mediator-in duced cutaneous reactions. MKS-492 and aminophylline were administered intraperitoneally 30 min prior to induc tion of reactions. MKS-492 at doses of 10 100 mg/kg sig nificantly inhibited PCA, histamine and 5-HT-induced cutaneous reactions in a dose-dependent manner. It also showed a tendency to inhibit the LTC4-induced cutaneous reaction. On the contrary, although aminophylline at doses of 10 and 30 mg/kg inhibited the PCA and hista mine-induced cutaneous reaction similarly to MKS-492, it had no effect on the 5-HT and LTC4-induced cutaneous reactions. 02 production Figure 9 indicates the effect of MKS-492 and aminophyl line on 02 production from guinea pig alveolar macro phages stimulated by PMA or PAF. MKS-492 at a concen tration of 100 pM inhibited the production of 02 by PAF, but failed to affect that caused by PMA. Amino phylline had no effect on 02 production at concentra tions of 100 and 300 pM. 
DISCUSSION
The bronchodilating property of theophylline is consi dered to be important for asthma treatment. MKS-492 showed about 10 times more potent bronchodilating activ ity than aminophylline in an in vitro experiment. Antigen induced bronchoconstriction in guinea pigs in vivo was also inhibited by MKS-492, which was similar to the effect of aminophylline. In addition, MKS-492 showed a potent inhibitory activity on PAF-induced bronchoconstriction. These results suggest that MKS-492 is expected to be effec tive for asthma in clinical trials through its bronchodilat ing activity. In addition, MKS-492 inhibited rat cutane ous allergic reactions, LTB4-induced leukocyte accumu lation in guinea pig airways, antigen or PLA2-induced histamine release and PAF-induced 02 production. These effects of MKS-492 seem to be beneficial for the treatment of allergic inflammation in the airway, which plays an important role in the production of bronchial asthma (19) (20) (21) (22) .
In 1989, we studied the anti-allergic mechanisms of in tracellular cyclic AMP-elevating agents and indicated that these agents, including theophylline, inhibit not only PCA but also mediator-induced cutaneous reactions elicit ed at the same time in the same rats (37) . In the present study, MKS-492 similarly inhibited not only PCA but also histamine and 5-HT-induced cutaneous reactions, and it showed a tendency to inhibit LTC4-induced cutane ous reaction. It is suggested, therefore, that MKS-492 in hibits the vascular permeability increase caused by media tors from activated mast cells, and that the action of MKS-492 contributes to the inhibition of PCA. It is in teresting that the inhibition of PCA was more potent than those against the mediator-induced cutaneous reactions, suggesting that another mechanism is also involved in the inhibition of PCA. As antigen-induced histamine release from mast cells in lung fragments of guinea pigs was in hibited by MKS-492, the action may also contribute to the inhibition of PCA. Aminophylline inhibited PCA and the histamine-induced cutaneous reaction similarly to MKS 492, although it failed to inhibit 5-HT and LTC4-induced cutaneous reactions. Higher doses of aminophylline may inhibit these reactions.
In the present results, MKS-492 exhibited potent inhib itory effects on PAF-induced reactions, whereas amino phylline in a similar dose range did not inhibit them. These results support the previous reports by Morley et al. (16, 17) . Regarding the role of PAF in bronchial asthma and allergic diseases, however, a definitive con clusion can not yet be drawn, although the existence of PAF in pathological lesions and the ability to elicit symp toms similar to disease have been confirmed by many in vestigators (38-41) . Furthermore, many specific PAF an tagonists have been examined, but none of them has been established as a remedy for asthma and allergic diseases. Although the molecular mechanisms of the inhibitory effects of MKS-492 on PAF-induced reactions have not been studied here, it may be a characteristic feature of MKS-492, not observed with aminophylline.
MKS-492 is a specific type III PDE inhibitor, and its potency is reported to be 2,000 times that of aminophyl line (16) . In the present results, the in vitro bronchodilat ing effect and inhibitory effects on PAF-induced reactions of MKS-492 were clearly more potent when compared to those of aminophylline.
In the other experiments, however, the inhibitory activity of MKS-492 was almost comparable to or slightly more potent than that of aminophylline when compared to the effective dosage. It is difficult, therefore, to discuss the differences observed in these two agents in relation to type III PDE inhibition. Further experiments on absorption, distribution and metabolism of these agents are necessary to clarify the mechanisms of action.
In conclusion, MKS-492, a specific type III PDE inhibi tor, exhibits more potent bronchodilating, anti-allergic and anti-inflammatory activities in guinea pigs and rats when compared to aminophylline. Further experiments, however, are necessary to elucidate the relationship be tween type III PDE inhibition and anti-allergic actions.
